Radiopharm Theranostics (ASX:RAD) Net Income From Continuing Operations: A$-38.34 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Radiopharm Theranostics Net Income From Continuing Operations?

Radiopharm Theranostics ASX:RAD +12.50% Net Income From Continuing Operations is A$-38.34 Mil as of Jun. 2025. The stock has 6 warning signs investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Radiopharm Theranostics's net income from continuing operations for the six months ended in Jun. 2025 was A$-18.70 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2025 was A$-38.34 Mil.

Radiopharm Theranostics Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Net Income From Continuing Operations Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25 Jun26
Net Income From Continuing Operations
-30.34 -34.61 -47.95 -38.34 -56.95

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Jun26
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only -24.76 0.00 -19.64 -18.70 0.00

Radiopharm Theranostics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-38.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of A$-38.34 Mil mean?
Radiopharm Theranostics (ASX:RAD) has a Net Income From Continuing Operations of A$-38.34 Mil as of Jun. 2025. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Radiopharm Theranostics and its competitors.
Is Radiopharm Theranostics' Net Income From Continuing Operations too high?
Radiopharm Theranostics' current Net Income From Continuing Operations is A$-38.34 Mil.
How does Radiopharm Theranostics' Net Income From Continuing Operations compare to VRTX and REGN?
Radiopharm Theranostics' Net Income From Continuing Operations of A$-38.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Biotechnology company?
A good Net Income From Continuing Operations depends on the Biotechnology industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current Net Income From Continuing Operations is A$-38.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Based on GuruFocus' analysis, Radiopharm Theranostics (ASX:RAD) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 10% below its estimated fair value. The current Net Income From Continuing Operations is A$-38.34 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Net Income From Continuing Operations is A$-38.34 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.